Contact us for free information or to start a free case review.
Zyprexa''s maker Eli Lilly & Co. announced it had warned doctors of using Zyprexa schizophrenia treatment amongst elderly patients with dementia. A letter was issued to U.S. doctors on January 15, 2004 to warn of increased risks of death and stroke when elderly patients with dementia were prescribed Zyprexa.
The Zyprexa warning closely resembles the April 2003 Johnson & Johnson warning for its schizophrenia drug Risperdal, which also warned of risks of stroke among elderly patients with dementia. Public Citizen consumer group has been very critical of the practice in prescribing schizophrenia drugs to treat symptoms of dementia since it has never been approved to treat it.
Contained in the Zyprexa warning letter was the observation that 3.5% of elderly patients with dementia being treated on Zyprexa in the trials died of all causes. This figure is more than twice the death rate of patients taking placebos. Zyprexa had global sales of $4.3 billion in 2003 alone, accounting for half of Lilly''s profits.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.